Literature DB >> 17096070

The model for end-stage liver disease score is useful for predicting economic outcomes in adult cases of living donor liver transplantation.

Takayuki Kogure1, Yoshiyuki Ueno, Naoki Kawagishi, Noriatsu Kanno, Yoko Yamagiwa, Koji Fukushima, Susumu Satomi, Tooru Shimosegawa.   

Abstract

BACKGROUND: The model for end-stage liver disease (MELD) is useful for assessing the recipients of liver transplants, namely, deceased-donor transplantation. The application of MELD for living donor liver transplantation (LDLT) is under investigation. Thus, the aim of this study was to analyze the impact of the MELD score in LDLT in Japan.
METHODS: Seventeen adult cases of LDLT during 2001 to 2005 were enrolled. Indications for LDLT were primary biliary cirrhosis, seven; liver cirrhosis, two; hepatocellular carcinoma (HCC), three; metabolic liver disease, one; primary sclerosing cholangitis, two; Caroli's disease, one; and biliary atresia, one. Total medical charges during the operative periods were retrospectively evaluated. The united network of organ sharing (UNOS) modified was obtained using preoperative clinical data.
RESULTS: The average medical expense of the 17 cases was approximately 97,901 US dollar. The UNOS-modified MELD score was 22.1. A statistically significant positive correlation was found between the MELD score and medical expense (P = 0.0086, rho = 0.657), and between the MELD score and the length of stay in the intensive care unit (ICU) (P = 0.0396, rho = 0.515). The cause of the liver disease leading to transplantation was not related to MELD score, medical expense, or length of ICU stay.
CONCLUSIONS: Although not originally designed for the application to LDLT, the MELD score is useful for predicting medical expenses in LDLT. Similar to those of deceased-donor liver transplantation, the disadvantage of high medical expenses associated with a high MELD score allow consideration of an earlier elective operation in suitable cases.

Entities:  

Mesh:

Year:  2006        PMID: 17096070     DOI: 10.1007/s00535-006-1887-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   6.772


  21 in total

1.  Selection and timing of liver transplantation in primary biliary cirrhosis.

Authors:  E Hashimoto; H Obata; K Tanikawa; F Ichida
Journal:  Hepatol Res       Date:  2001-07       Impact factor: 4.288

2.  Burden of liver disease in the United States: summary of a workshop.

Authors:  W Ray Kim; Robert S Brown; Norah A Terrault; Hashem El-Serag
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

3.  Living donor liver transplantation in Japan and Kyoto University: what can we learn?

Authors:  Koichi Tanaka; Takako Yamada
Journal:  J Hepatol       Date:  2005-01       Impact factor: 25.083

4.  The economic impact of MELD on liver transplant centers.

Authors:  David A Axelrod; Alan J Koffron; Talia Baker; Patrice Al-Saden; Irma Dixler; Gwen McNatt; Scott Sumner; Mike Vaci; Michael Abecassis
Journal:  Am J Transplant       Date:  2005-09       Impact factor: 8.086

5.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.

Authors:  M Malinchoc; P S Kamath; F D Gordon; C J Peine; J Rank; P C ter Borg
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

6.  Retrospective evaluation of tumor-mass-reduction therapy for the prognosis of recurrent hepatocellular carcinoma.

Authors:  Emiko Mikami; Noriatsu Kanno; Yoshiyuki Ueno; Tooru Shimosegawa
Journal:  Hepatol Int       Date:  2007-10-18       Impact factor: 6.047

7.  Short-term postliver transplant survival after the introduction of MELD scores for organ allocation in the United States.

Authors:  Hwan Y Yoo; Paul J Thuluvath
Journal:  Liver Int       Date:  2005-06       Impact factor: 5.828

Review 8.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

9.  Predictive models in cirrhosis: correlation with the final results and costs of liver transplantation in Chile.

Authors:  R Zapata; F Innocenti; E Sanhueza; R Humeres; H Rios; L Suarez; J M Palacios; M Rius; J Hepp
Journal:  Transplant Proc       Date:  2004 Jul-Aug       Impact factor: 1.066

10.  Liver transplantation for hepatitis B.

Authors:  Steven-Huy Bui Han; Paul Martin
Journal:  Hepatol Res       Date:  2004-08       Impact factor: 4.288

View more
  6 in total

1.  Living donor liver transplantation for hepatocellular carcinoma: defining criteria to extend indications.

Authors:  Irinel Popescu
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

2.  The current economic burden of cirrhosis.

Authors:  Guy W Neff; Christopher W Duncan; Eugene R Schiff
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

Review 3.  Quality of life in cirrhosis.

Authors:  Anthony Loria; Carey Escheik; N Lynn Gerber; Zobair M Younossi
Journal:  Curr Gastroenterol Rep       Date:  2013-01

Review 4.  The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future).

Authors:  Yoichi Ishizaki; Seiji Kawasaki
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

5.  Model for end-stage liver disease (MELD) score and cost-effectiveness on living donor liver transplantation.

Authors:  Takafumi Ichida; Yutaka Narita; Romi Murakami
Journal:  J Gastroenterol       Date:  2006-10       Impact factor: 6.772

6.  Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients.

Authors:  Christian E Oberkofler; Philipp Dutkowski; Reto Stocker; Reto A Schuepbach; John F Stover; Pierre-Alain Clavien; Markus Béchir
Journal:  Crit Care       Date:  2010-06-15       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.